

CLEARBRIDGE HEALTH LIMITED
(Company Registration No. 201001436C)
(the "**Company**")

ANNOUNCEMENT PURSUANT TO RULE 706A OF THE CATALIST RULES

Pursuant to Rule 706A of the Listing Manual Section B: Rules of Catalist ("**Catalist Rules**") of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**"), the board of directors (the "**Board**") of Clearbridge Health Limited (the "**Company**") wishes to announce the following transactions that occurred during the six-month financial period from 1 July 2023 to 31 December 2023.

DISPOSAL OF SHARES IN BIOLIDICS LIMITED

The Company announced on 21 July 2023, that Clearbridge BSA Pte. Ltd. ("**CBBSA**"), a wholly-owned subsidiary of the Company, entered into an agreement ("**SPA**") for the sale of 57,123,300 ordinary shares it holds in Biolidics Limited ("**Biolidics**") ("**Sale Shares**") to Mr Wong Kong Leong ("**Purchaser**") by way of a married deal through the SGX-ST (as defined below) (the "**Disposal**"). The Sale Shares represent 10.22% of the total issued and paid up share capital of Biolidics as at the date of the SPA.

The Disposal was completed on 21 July 2023 ("**Completion**") and upon Completion, CBBSA no longer holds any shares in Biolidics.

Consideration	The aggregate consideration for the Disposal under the SPA is S\$932,823.49 or S\$0.01633 per Sale Share (" Sale Price "), satisfied in cash and in full on the completion of the Disposal. The consideration was arrived at, <i>inter alia</i> , on a willing buyer-willing seller basis, after negotiations between the parties, taking into account the current market price of the shares of Biolidics (" Biolidics Shares ") of S\$0.014 based on the closing price of the Biolidics Shares as at 20 July 2023 being the last full market day the Biolidics Shares were traded prior to the date of the SPA, the downward trend in the market price of the Sale Shares over the last six (6) months as well as the positive cash inflow available to the Group arising from the Disposal.
Market Value	S\$799,726 based on the closing price of the shares of Biolidics of S\$0.014 as at 20 July 2023, being the last full market day the Biolidics Shares were traded prior to the date of the SPA.

Please refer to the Company's announcement dated 21 July 2023 in relation to the Disposal for further details.

BY ORDER OF THE BOARD

Yee Pinh Jeremy
Chief Executive Officer and Executive Director

29 February 2024

*This announcement has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with Rules 226(2)(b) and 753(2) of the SGX-ST Listing Manual Section B: Rules of Catalist. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr David Tham, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*